Office of Licensing & Ventures

Home


 OLV Overview

The Office of Licensing & Ventures (OLV) is responsible for patents, technology licenses and new venture development for Duke University and Medical Center.  Through direct, daily interaction with faculty, small and large businesses, and venture investors, we build strong relationships and strong agreements to translate academic discoveries into commercial products that benefit society, impact public health, and improve the quality of life. 

Latest News

PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals
January 7, 2010

Frost & Sullivan Names Precision BioSciences’ Directed Nuclease Editor ‘Technology Innovation of the Year’
May 12, 2009

Bright View raises $10M
June 14, 2008
Money to fund launch of optical films

Leading Protein Engineering Executive Joins
April 15, 2008

Genes May Help Some Quit Smoking
April 2, 2008
Certain DNA is linked to better results, study finds

Trevena, Inc. Announces $24 Million Series A Financing
March 5, 2008
Drug Discovery Company to Focus on G-Protein Coupled Receptors

Celsion to Proceed with Phase II Pivotal Breast Cancer Trial after Receiving Supportive FDA Response
January 15, 2008
Expects to Initiate Trial in Ten US Centers

Banked Blood Loses Ability to Deliver Oxygen to Tissues
October 8, 2007

Genetic Variant Linked to Odor Perception
September 16, 2007

Separating the Brain's 'Bad' from 'Good' Iron
August 23, 2007
Duke chemists have found a way, by using 'pro-chelators' wrapped in chemical 'cages'

Mice Provide Important Clues to Obsessive-Compulsive Disorder
August 22, 2007

Sentillion's Growth Continues With Strong Q2; Signs 9 New Customers; Sells 94,130 Licenses
July 12, 2007

New HIV Test May Predict Drug Resistance
January 7, 2007
DURHAM, N.C. -- Researchers at Duke University Medical Center have developed a highly sensitive test for identifying which drug-resistant strains of HIV are harbored in a patient's bloodstream.

See all news